Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease.

Lomas DA, Lipson DA, Miller BE, Willits L, Keene O, Barnacle H, Barnes NC, Tal-Singer R; Losmapimod Study Investigators.

J Clin Pharmacol. 2012 Mar;52(3):416-24. doi: 10.1177/0091270010397050. Epub 2011 Nov 16.

PMID:
22090363
2.

Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience.

Celli B, Vestbo J, Jenkins CR, Jones PW, Ferguson GT, Calverley PM, Yates JC, Anderson JA, Willits LR, Wise RA; Investigators of the TORCH Study.

Am J Respir Crit Care Med. 2011 Feb 1;183(3):317-22. doi: 10.1164/rccm.201004-0665OC. Epub 2010 Sep 2.

PMID:
20813884
3.

Cardiovascular events in patients with COPD: TORCH study results.

Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Crim C, Willits LR, Yates JC, Vestbo J; TORCH Investigators.

Thorax. 2010 Aug;65(8):719-25. doi: 10.1136/thx.2010.136077.

PMID:
20685748
4.

Reported pneumonia in patients with COPD: findings from the INSPIRE study.

Calverley PMA, Stockley RA, Seemungal TAR, Hagan G, Willits LR, Riley JH, Wedzicha JA; Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) Investigators.

Chest. 2011 Mar;139(3):505-512. doi: 10.1378/chest.09-2992. Epub 2010 Jun 24.

PMID:
20576732
5.

Adherence to inhaled therapy, mortality and hospital admission in COPD.

Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, Knobil K, Willits LR, Yates JC, Jones PW.

Thorax. 2009 Nov;64(11):939-43. doi: 10.1136/thx.2009.113662. Epub 2009 Aug 23.

PMID:
19703830
6.

Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study.

Ferguson GT, Calverley PMA, Anderson JA, Jenkins CR, Jones PW, Willits LR, Yates JC, Vestbo J, Celli B.

Chest. 2009 Dec;136(6):1456-1465. doi: 10.1378/chest.08-3016. Epub 2009 Jul 6.

PMID:
19581353
7.

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study.

Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J.

Respir Res. 2009 Jun 30;10:59. doi: 10.1186/1465-9921-10-59.

8.

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.

Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J.

Eur Respir J. 2009 Sep;34(3):641-7. doi: 10.1183/09031936.00193908. Epub 2009 May 14.

9.

Yes, steroids are safe in infants with asthma-like symptoms.

Bisgaard H, Allen D, Milanowski J, Kalev I, Willits L, Davies P.

Pediatrics. 2004 Sep;114(3):904. No abstract available.

PMID:
15342883
10.

Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing.

Bisgaard H, Allen DB, Milanowski J, Kalev I, Willits L, Davies P.

Pediatrics. 2004 Feb;113(2):e87-94.

PMID:
14754977
11.

Withdrawal from treatment as an outcome in the ISOLDE study of COPD.

Calverley PM, Spencer S, Willits L, Burge PS, Jones PW; IOSLDE Study Group.

Chest. 2003 Oct;124(4):1350-6.

PMID:
14555565
12.

Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations.

Jones PW, Willits LR, Burge PS, Calverley PM; Inhaled Steroids in Obstructive Lung Disease in Europe study investigators.

Eur Respir J. 2003 Jan;21(1):68-73.

Supplemental Content

Loading ...
Support Center